Review Article
Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
Table 2
Clinically significant CYP3A4 inducers, inhibitors, and substrates.
| CYP3A4 inducers | CYP3A4 inhibitors | CYP3A4 substrates |
| Dexamethasone | Calcium channel blockers: amiodarone, verapamil | Statins: atorvastatin, lovastatin, and simvastatin (not pravastatin) (not rosuvastatin) |
| Anticonvulsants: phenytoin, carbamazepine | Azole antifungals: itraconazole, voriconazole, and ketoconazole | Calcium channel blockers: amlodipine, diltiazem, felodipine, nifedipine, and verapamil |
| Phenobarbital | | |
| Rifampin | Macrolide antibiotics: erythromycin, and clarithromycin (not azithromycin) | |
| St. John’s wort | | |
| HIV antivirals: nonnucleoside reverse transcriptase inhibitors: efavirenz, and nevirapine | HIV antivirals: protease inhibitors: indinavir, nelfinavir, and ritonavir | |
| Pioglitazone | | |
|
|